Antengene Corporation Limited (HK:6996) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Antengene Corporation Limited has announced that the Malaysian National Pharmaceutical Regulatory Agency approved a New Drug Application for XPOVIO® for two new indications in the treatment of multiple myeloma. This milestone reflects the company’s commitment to expanding its oncology portfolio and the potential for XPOVIO® to offer novel treatment options for patients. The company advises shareholders and potential investors to exercise caution when dealing in its shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.